Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia   A parallel global Phase 2/3 study with orally administered opaganib for severe COVID-19 is approximately 50% enrolled - on track to ...
View HTML
Toggle Summary RedHill Biopharma to Present at German Equity Forum 2020
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg , RedHill’s Chief Business Officer, will present a corporate overview and host ...
View HTML
Toggle Summary RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
Q3/2020 net revenues of approximately $21 million , with gross profit of $10.6 million , or approximately 51% , up from $6.7 million   and approximately 32% in Q2/2020 -- Strong growth for Talicia ®   with approximately 300 % quarter- over -quarter prescription growth   and rapid expansion of the ...
View HTML
Toggle Summary RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, ...
View HTML
Toggle Summary RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036 -- Combination of opaganib and RHB-107 demonstrated potent antitumor effect and ...
View HTML
Toggle Summary RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
  H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite declining efficacy, physicians are still   prescribing these regimens   counter to ACG guidelines ,   which ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
RHB-204 Phase 3 study in pulmonary NTM   infections is planned to be initiated in the coming weeks -- Orphan Drug Designation , along with RHB-204’s FDA QIDP priority designation, will extend U.S.   potential market exclusivity   to a total of 12 years TEL AVIV, Israel and RALEIGH, N.C. , Oct. ...
View HTML
Toggle Summary RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
         Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing   further strengthen s manufacturing capabilities and capacity ,   in preparation for potential emergency use applications  --        Enrollment in the g lobal Phase 2/3 COVID-19 study ...
View HTML
Toggle Summary RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
RedHill obtains Israel rights to Movantik ® from AstraZeneca ,   giv ing   RedHill global rights, excluding Europe and Canada -- Movantik approved for opioid-induced constipation   in Israel   under the brand name Mov e ntig ® -- RedHill to evaluate partnering opportunities for commercialization of ...
View HTML
Toggle Summary RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S.   Phase 2 study with opaganib in COVID-19  -- The U.S.   Phase 2 study   is 75% enrolled with data expected later this quarter -- In parallel, e nrollment ...
View HTML